Faustine Dalon

Faustine Dalon

Auto-generated profile, based on publicly available information

Faustine Dalon

PELyon, PharmacoEpidemiologie Lyon, 210 Avenue Jean Jaurès, Lyon, F-69007

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
IDIsabelle Durieu
Isabelle Durieu
FDFaustine Dalon
Faustine Dalon
QRQuitterie Reynaud
Quitterie Reynaud
LLLydie Lemonnier
Lydie Lemonnier
CDClémence Dehillotte
Clémence Dehillotte
MBManon Belhassen
Manon Belhassen

1 August 2021 in Vaccine
Verified
Journal Article
Closed access
FDFaustine Dalon
Faustine Dalon
LMLaureen Majed
Laureen Majed
MBManon Belhassen
Manon Belhassen
FJFlore Jacoud
Flore Jacoud
MBMarjorie Bérard
Marjorie Bérard
JBJean-Jacques Baldauf
Jean-Jacques Baldauf

1 December 2019 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
FDFaustine Dalon
Faustine Dalon
GDGilles Devouassoux
Gilles Devouassoux
MBManon Belhassen
Manon Belhassen
GNGaëlle Nachbaur
Gaëlle Nachbaur
CSCamille Correia Da Silva
Camille Correia Da Silva
EGEric Van Ganse
Eric Van Ganse
Purpose: This study assessed therapy persistence in patients with chronic obstructive pulmonary disease (COPD) in France, and the impact of non-persistence on exacerbations and described COPD-related healthcare resource use (HRU). Methods: Patients aged ≥45 years who received ≥1 dispensed bronchodilator per quarter over three consecutive quarters between 2007 and 2014 and initiated specific COPD therapy were selected from the Echantillon Généraliste des Bénéficiaires (EGB) database. Persistence, defined as the absence of dispensing gaps of >90 days, was measured at 12 months. Exacerbations were compared between persistent and non-persistent patients during follow-up after patient matching and adjustment for confounding factors. COPD-related HRU during follow-up was described. Results: Among 4020 patients with COPD, 2164 initiated a specific therapy. Of these, 54.4% stopped treatment within 12 months. Persistence with all COPD therapy regimens was low, particularly for inhaled corticosteroid (ICS; 25.6%) and ICS/twice-daily long-acting beta-agonist (39.4%) regimens. Among 721 persistent patients who were matched with 721 non-persistent patients, there was no difference in the number of moderate or severe exacerbations at 12 months. However, medical procedures (for instance, pulmonary function testing and chest X-rays) were more frequently observed among persistent patients than among non-persistent patients, suggesting worse disease severity. Conclusion: Patients receiving specific treatment(s) for COPD demonstrated low persistence for all examined therapy regimens, with no clear impact of persistence status on the frequency of exacerbations at 12 months.

1 May 2020
Verified
Conference Paper
Open access
Vincent CottinVincent Cottin
Vincent Cottin
PSPaolo Spagnolo
Paolo Spagnolo
PBPhilippe Bonniaud
Philippe Bonniaud
MNM. Nolin
M. Nolin
FDF. Dalon
F. Dalon
MBManon Belhassen
Manon Belhassen